
Invacare Corporation IVC
Quarterly report 2023-Q1
added 05-15-2023
Invacare Corporation General and Administrative Expenses 2011-2026 | IVC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Invacare Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 227 M | 232 M | 236 M | 260 M | 282 M | 297 M | 304 M | 320 M | 384 M | 402 M | 415 M | 422 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 422 M | 227 M | 315 M |
Quarterly General and Administrative Expenses Invacare Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.8 M | - | 55.4 M | 58.6 M | 60.6 M | - | 56.1 M | 63.8 M | 58.8 M | - | 55.5 M | 57.4 M | 119 M | - | 63.5 M | 68.3 M | 65.2 M | - | 69.9 M | 73.8 M | 71.3 M | - | 75.9 M | 75.7 M | 72.5 M | - | 77.7 M | 78.7 M | 72.8 M | - | 77.5 M | 82.4 M | 81.2 M | - | 98.2 M | 100 M | 96.8 M | - | 97.6 M | 104 M | 103 M | - | 103 M | 104 M | 101 M | - | 104 M | 112 M | 106 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | 53.8 M | 80.5 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 13.99 | -0.36 % | $ 2.1 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
44.6 M | $ 31.34 | 0.38 % | $ 1.44 B | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.43 | 0.15 % | $ 119 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cognyte Software Ltd.
CGNT
|
163 M | $ 6.92 | 4.53 % | $ 497 M | ||
|
ClearPoint Neuro
CLPT
|
12 M | $ 13.22 | -12.8 % | $ 357 M | ||
|
Bio-Rad Laboratories
BIO
|
814 M | $ 269.27 | -0.06 % | $ 7.6 B | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
894 M | $ 39.99 | 0.26 % | $ 5.96 K | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 74.5 | 1.4 % | $ 110 B | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 4.49 | -2.18 % | $ 167 M | ||
|
Electromed
ELMD
|
39.3 M | $ 24.25 | 1.38 % | $ 205 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 46.81 | 1.83 % | $ 1.45 B | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
29.6 M | $ 9.32 | -8.72 % | $ 266 M | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
8.41 M | $ 14.04 | 0.57 % | $ 907 M | ||
|
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | ||
|
IRadimed Corporation
IRMD
|
15.9 M | $ 101.94 | 1.43 % | $ 1.29 B | ||
|
Establishment Labs Holdings
ESTA
|
140 M | $ 75.77 | -3.23 % | $ 2.13 B | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.55 | -0.16 % | $ 122 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 71.06 | 1.09 % | $ 3.88 B | ||
|
Globus Medical
GMED
|
1.18 B | $ 96.03 | -0.19 % | $ 13 B | ||
|
Medtronic PLC
MDT
|
10.8 B | $ 96.4 | -0.27 % | $ 124 B | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 5.01 | -5.02 % | $ 740 M | ||
|
Pulmonx Corporation
LUNG
|
102 M | $ 1.59 | -2.68 % | $ 62.2 M | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 1.93 | -11.06 % | $ 1.17 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 11.47 | -1.04 % | $ 883 M |